Looking beyond the hype: Applied AI and machine learning in translational medicine

Abstract

Big data problems are becoming more prevalent for laboratory scientists who look to make clinical impact. A large part of this is due to increased computing power, in parallel with new technologies for high quality data generation. Both new and old techniques of artificial intelligence (AI) and machine learning (ML) can now help increase the success of translational studies in three areas: drug discovery, imaging, and genomic medicine. However, ML technologies do not come without their limitations and shortcomings. Current technical limitations and other limitations including governance, reproducibility, and interpretation will be discussed in this article. Overcoming these limitations will enable ML methods to be more powerful for discovery and reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.

Machine Learning in Cardiology—Ensuring Clinical Impact Lives Up to the Hype

“…This is often a very tedious process, and ML-based feature engineering can be applied to identify chemical information that would be useful to prioritize for clinical investigation. 98 These principles can be applied to develop or reposition drugs to more optimally treat CVD.…”

Mitochondria under the spotlight: On the implications of mitochondrial dysfunction and its connectivity to neuropsychiatric disorders

“…To address these limitations, AI-augmented decision-making platforms coupled with machine learning processes such as reinforcement, semi-supervised, transfer, active or multi-task learning (for detailed review, see [122] can offer orders of magnitude increases in pool search. These platforms navigate synthetically accessible chemical space by subjecting commercially available molecules to chemical reactions at every step of the iterative virtual synthesis process, increasing likelihood of new drug discovery [123] .…”

Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?

“…Artificial intelligence (AI), mainly through machine learning (ML, a subtype of AI), provides algorithms capable of learning from data. According to the U.S. Food and Drug Administration, AI is "the science and engineering of making intelligent machines", while ML is "an AI tool that can be used to design and train software algorithms to learn from and act on data" [10]. ML algorithms can uncover complex data patterns and can be stowed in one of the following categories: (i) supervised learning (ii), unsupervised learning, or (iii) reinforcement learning [11].…”